This article is more than 5 years old. Information may no longer be current.
Top stories in gastroenterology: sleep quality improvement in treating GI conditions, FDA approves Xeljanz
Click Here to Manage Email Alerts
Among the top stories in gastroenterology is an expert statement that the upregulation of proinflammatory cytokines and altered visceral and somatic perception caused by sleep disruption have significant implications for a variety of gastrointestinal conditions. Xeljanz received FDA approval for the treatment of moderately to severely active ulcerative colitis. Other stories include a meta-analysis showing EndoBarrier, a device that mimics small bowel mechanisms, improved glycemic control and insulin resistance in patients with type 2 diabetes and obesity, more patients with Crohn’s disease could benefit from diverting loop ileostomy, Thryve, a monthly microbiome testing service, received $1.4 million in funding.
Sleep quality improvement a ‘tremendous opportunity’ in treating GI conditions
The upregulation of proinflammatory cytokines and altered visceral and somatic perception caused by sleep disruption have important implications for a variety of gastrointestinal conditions, experts told Healio Gastroenterology and Liver Disease. Read More.
FDA approves Xeljanz for moderate-to-severe UC
The FDA has expanded the approval of Xeljanz to include use by adults with moderately to severely active ulcerative colitis. Read More.
EndoBarrier improves glycemic control in patients with diabetes, obesity
EndoBarrier, an endoscopic device that mimics the small bowel mechanisms of Roux-en-Y gastric bypass, improved glycemic control and insulin resistance in patients with type 2 diabetes and obesity, according to a meta-analysis published in Diabetes Care. Read More.
Diverting loop ileostomy underused in Crohn’s disease
According to a study presented at the American Society of Colorectal Surgeons Annual Scientific Meeting in Nashville, more patients with Crohn’s disease could benefit from diverting loop ileostomy due to their high risk for anastomotic leak. Read More.
Microbiome testing service receives $1.4 million in funding
Thryve, a monthly microbiome testing and personalized probiotics subscription service founded in 2016, announced it received $1.4 million in funding from several investment firms. Read More.